TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit?

J Heart Lung Transplant. 2003 May;22(5):501-4. doi: 10.1016/s1053-2498(02)00525-9.
No abstract available

Publication types

  • Review

MeSH terms

  • Coronary Artery Disease / drug therapy*
  • Coronary Artery Disease / immunology
  • Coronary Artery Disease / prevention & control
  • Graft Occlusion, Vascular / immunology
  • Graft Occlusion, Vascular / prevention & control*
  • Heart Transplantation / adverse effects
  • Heart Transplantation / immunology*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Protein Kinase Inhibitors*
  • Protein Kinases*
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases
  • Tunica Intima / immunology
  • Tunica Intima / pathology*

Substances

  • Immunosuppressive Agents
  • Protein Kinase Inhibitors
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus